Vela Hernández José Miguel,Zamanillo-Castanedo Daniel,Plata-Salaman Carlos
申请号：
NZ61211911
公开号：
NZ612119A
申请日:
2011.12.02
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
The disclosure relates to the use a sigma ligand for the manufacture of a medicament for use in the prevention and/or treatment of bone cancer pain. The pain may be selected from acute and/or chronic pain developed as a consequence of bone cancer, preferably neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure. The sigma ligand may have a structure according to structural formula (I), wherein, R1, R2, R3, R4, R5, R6 and n are as defined within the specification and the ligand may be combined with at least one opioid or opiate compound. Example compounds include: 4-{ 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl} morpholine, 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine, 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole, 1-(3,4-Dichlorophenyl)-4,5-dimethyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole, 1-{ 2-[1-(3,4-Dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yloxy]ethyl} piperidine, 4-{ 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]butyl} morpholine, 1-(3,4-Dichlorophenyl)-3-[4-(pyrrolidin-1-yl)butoxy]-1H-pyrazole, 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N,N-diethylbutan-1-amine, N-benzyl-4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-methylbutan-1-amine, 4-[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yloxy]-N-(2-methoxyethyl)-N-methylbutan-1-amine.
